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Identity 
Other names: HCP, HCPH, HPTP1C, PTP-1C, SH-
PTP1, SHP-1, SHP-1L, SHP1 
HGNC (Hugo): PTPN6 
Note 
Orientation: plus strand. 
DNA/RNA 
Description 
The human PTPN6 gene is divided in 17 exons 
spanning a length of 14740 bp. A notable feature of the 
PTPN6 gene is that it has two promoter regions. 
Whereas the distal promoter, P1, located upstream of 
the very short exon 1 (also known as exon 1a) is active 
in epithelial cells, the proximal promoter P2 that 
initiates gene transcription from exon 2 (known as exon 
1b), is utilized by the hematopoietic cells. The function 
of P1 promoter has been partially elucidated, while the 
structure and regulatory mechanism of the P2 promoter 
remain essentially unknown. 
Recent findings, characterized the hematopoietic cell-
specific P2 promoter of PTPN6 gene as well as 
identified the PU.1 transcription factor as the activator 
of the P2 promoter. 
Transcription 
There are three transcript variants: 
The variant 1 represents the predominant variant and 
encodes the shortest isoform. 
The variant 2 originates by an alternate 5' terminal exon 
compared to transcript variant 1, resulting in an isoform 
(2) with a distinct and longer (by 2 aa) N-terminus, 
compared to isoform 1. 
The variant 3 uses an alternate 5' terminal exon, and an 
alternate acceptor splice site at the penultimate exon, 
compared to transcript variant 1, resulting in a longer 
isoform (3, also known as 70 kDa SHP-1L protein) 
with distinct N and C termini, compared to isoform 1. 
Protein 
Description 
PTPN6 contain two adjacent NH2 - terminal SH2 
domains, two tandem Src homology (SH2) domains, a 
catalytic domain, and a -COOH terminal tail of 100 
amino-acid residues. 
Expression 
PTPN6 tyrosine phosphatase is encoded by the PTPN6 
gene and expressed primarily in the hematopoietic and 
epithelial cells. 
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Schematic representation of the human PTPN6 gene. Adapted from Wu et al., 2003. 
 
 
Function 
PTPN6 plays a peculiar role in the maturation and 
functional differentiation of lymphoid and myeloid 
cells as underlined by the aberrant proliferation and 
impaired hematopoiesis in the "motheaten" (me) mice 
that display defects in the Shp-1 gene expression.  
The role of PTPN6 in hematopoiesis has been shown in 
motheaten and viable motheaten (meν) mice, 
characterized by mutations at the Shp-1 locus. The 
Shp-1 mRNA from me bone marrow cells have a 101 
bp frameshift deletion in the coding region of the N-
terminal SH2 domain, while meν bone marrow cells 
have an in-frame 15 bp deletion or a 69 bp in-frame 
insertion within the PTPase catalytic domain.  
Shp-1 acts in the immune and other hematopoietic cells 
by inhibiting signaling through receptors for cytokines, 
growth factors and chemokines as well as receptors 
involved in the immune responses and programmed 
cell death.  
Moreover, PTPN6 acts as tumor suppressor and loss of 
its expression has been identified in the whole spectrum 
of myeloid and lymphoid malignancies. 
According to Gilfillan, PTPN6 is found to be  
constitutively associated with FcεRI, with an opponing 
roles in FcεRI-mediated mast cell signaling. The study 
demonstrated that PTPN6 caused the decreased 
phosphorylation of FcεRI and Syk, but, also, an 
enhanced phosphorylation of JNK and an increased of 
the TNF production is observed. This study, suggests 
that PTPN6 may play a negative role proximal to 
FcεRI. 
It was also demonstrated that the PTPN6 protein 
tyrosine phosphatase negatively modulates the glucose 
homeostasis and insulin activity, through a 
dephosphorylation of transmembrane glycoprotein 
Carcinoembryonic Antigen-related Cell Adhesion 
Molecule-1 (CEACAM-1). 
The data obtained from in vitro studies, suggested that 
the deficiency of PTPN6 was associated with the 
increase in insulin-evoked tyrosin phosphorylation of 
the insulin receptor, IRS-1 and IRS-2, as well as 
enhanced activation of PI3K and Akt in liver and 
skeletal muscle. 
Moreover, the activation of PTPN6, through a PKC-δ 
and p38α MAPK actions on PDGFRβ is involved in 
hyperglycemia and causes an increase vascular cell 
apoptosis and diabetic vascular complications. 
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Crystal structure of human protein tyrosine phosphatase SHP-1. The blue region represents the N-terminal of protein, while the red 
region represents the C-terminal of protein. 
 
Mutations 
Note 
The absence or impaired function of PTPN6 in the 
homozygous state causes the development of the 
motheaten phenotype in mice, an autosomal recessive 
condition with focal skin inflammation and the absence 
of hair. Failure of neutrophils to undergo apoptosis 
results in the accumulation of these cells in the 
peripheral blood, skin, lung and spleen of affected 
mice. 
Somatic 
A pathologically similar extensive skin infiltration by 
neutrophils is present in Pyoderma gangrenosum (PG) 
and Sweet's syndrome (SW), two uncommon 
neutrophilic dermatoses of unknown origin. Isoforms 
resulting from deletions of exons 2, 5, 11, and 15 and 
retention of intron 1 or 5 were identified in a patients 
with a familial case of SW, who had a neonatal onset of 
an inflammatory disorder with skin lesions and a 
biopsy specimen consistent with SW. These isoforms 
were associated with a heterozygous E441G mutation 
and a heterozygous 1,7-kbp deletion in the promoter 
region of the PTPN6 gene. The E441G mutation 
changes the hydrophilic, negatively charged amino acid 
glutamate to the hydrophobic nonpolar, aliphatic amino 
acid glycine, thereby potentially affecting the tertiary 
structure of PTPN6. SW an acute febrile neutrophilic 
dermatoses appears in several clinical forms as 
idiopathic, tumor associated, postinfectious and drug 
induced (for example after an administration of 
granulocyte macrophage colony stimulating factor). 
SW and PG have strong associations with 
hematological tumors. Recent studies have shown that 
patient with leukemia and lymphoma had methylated a 
P2 promoter in the PTPN6 gene, causing the absence of 
PTPN6 protein.  
PTPN6 is expressed at low level in non-hematopoietic 
cells while higher levels of this protein are found in 
hematopoietic precursors. PTPN6 promoter 
methylation causes loss of expression in leukemias, 
which results in the activation of the JAK/STAT 
pathway. PTPN6 plays a role in chronic myelogenous 
leukemia transformation and progression: it seems to 
be physically associated with BCR-ABL being able 
both to block BCR-ABL-dependent transformation and 
to mediate PP2A induced BCR-ABL proteosome-
degradation. The tyrosine phosphatase PTPN6 plays a 
prominent role as resistance determinant of Imatinib 
(IMA) treatment response in Chronic Myelogenous 
Leukemia cell lines (sensitive/KCL22-S and 
resistant/KCL22-R). 
The lack of PTPN6 expression is frequent in malignant 
T cells and results from methylation of the PTPN6 gene 
promoter. Loss of PTPN6 enhances JAK3/STAT3 
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signaling and decreases proteosome degradation of 
JAK3 and NPM-ALK in ALK + anaplastic large-cell 
lymphoma. 
According to Wu's research, in most human Burkitt's 
lymphoma cell lines, the expression of SHP-1 is 
decreased suggesting a role of SHP-1 in a developing 
of Burkitt's lymphoma, a non-Hodgkin's lymphoma, 
associated with EBV infection.  
Moreover the activity of PTPN6, is also implicated in a 
breast cancer, ovarian cancer, prostate cancer, and 
pancreatic cancer. 
Implicated in 
T-cell lymphomas 
Disease 
Cutaneous T-cell lymphoma (CTCL) is generally 
classified as a type of non-Hodgkin's lymphoma, and it 
represents a spectrum of diseases composed of 
malignant clonal helper T lymphocytes of the CD4 
phenotype. Widely known variants include Sezary 
syndrome, Woringer-Kolopp disease (Pagetoid 
Reticulosis), CD8+ T-cell lymphoma, granulomatous 
slack skin, peripheral T-cell lymphoma, angiocentric 
lymphoma, adult T-cell leukemia/lymphoma, large-cell 
or anaplastic lymphoma, and lymphomatoid 
granulomatosis. Poikiloderma atrophicans vasculare, 
small and large plaque parapsoriasis, alopecia 
mucinosa, and lymphomatoid papulosis likely represent 
early forms of CTCL, but there is a problem to whether 
these represent CTCL or separate premalignant entities. 
Accurate diagnosis of early CTCL is difficult because 
of the varied clinical and histologic expressions of the 
disease and because of a lack of uniformity regarding 
diagnosis and treatment. 
Prognosis 
Treatment regimens in CTCL include skin-directed 
therapies with UVA irradiation, topical chemotherapy 
with mechlorethamine (nitrogen mustard) and 
carmustine, and electron beam radiation, as well as 
systemic therapies such as chemotherapy and 
interferons. 
Acute myeloid leukemia 
Note 
The first hint that A-to-I RNA editing has fundamental 
implications in leukemic disorders derives from 
Beghini and co-authors, who detected altered editing 
events in the protein tyrosine phosphatase 
(PTPN6/SHP-1) transcript of patients affected by AML 
(Galeano et al., 2012). 
The analysis of PTPN6 mRNA revealed a multiple A-I 
editing conversion of A7866, a branch site in IVS3 of 
PTPN6 mRNA causing the retention of IVS1. 
Disease 
Adult acute myeloid leukemia (AML) is a type of 
cancer in which the bone marrow makes abnormal 
myeloblasts (a type of white blood cell), red blood 
cells, or platelets. Adult acute myeloid leukemia 
(AML) is a cancer of the blood and bone marrow. This 
type of cancer usually gets worse quickly if it is not 
treated. It is the most common type of acute leukemia 
in adults. AML is also called acute myelogenous 
leukemia, acute myeloblastic leukemia, acute 
granulocytic leukemia, and acute nonlymphocytic 
leukemia. Most AML subtypes are based on how 
mature (developed) the cancer cells are at the time of 
diagnosis and how different they are from normal cells. 
Acute promyelocytic leukemia (APL) is a subtype of 
AML that occurs when parts of two genes stick 
together. APL usually occurs in middle-aged adults. 
Symptoms of APL may include both bleeding and 
forming blood clots. 
Prognosis 
Chemotherapy is a cancer treatment that uses drugs to 
stop the growth of cancer cells, either by killing the 
cells or by stopping them from dividing. When 
chemotherapy is taken by mouth or injected into a vein 
or muscle, the drugs enter the bloodstream and can 
reach cancer cells throughout the body (systemic 
chemotherapy). When chemotherapy is placed directly 
into the spinal column (intrathecal chemotherapy), an 
organ, or a body cavity such as the abdomen, the drugs 
mainly affect cancer cells in those areas (regional 
chemotherapy). Intrathecal chemotherapy may be used 
to treat adult AML that has spread, or may spread to the 
brain and spinal cord. Combination chemotherapy is 
treatment using more than one anticancer drug.  
Radiation therapy is a cancer treatment that uses high-
energy x-rays or other types of radiation to kill cancer 
cells or keep them from growing. There are two types 
of radiation therapy. External radiation therapy uses a 
machine outside the body to send radiation toward the 
cancer. Internal radiation therapy uses a radioactive 
substance sealed in needles, seeds, wires, or catheters 
that are placed directly into or near the cancer. Stem 
cell transplant is a method of giving chemotherapy and 
replacing blood-forming cells that are abnormal or 
destroyed by the cancer treatment. Stem cells 
(immature blood cells) are removed from the blood or 
bone marrow of the patient or a donor and are frozen 
and stored. After the chemotherapy is completed, the 
stored stem cells are thawed and given back to the 
patient through an infusion. These reinfused stem cells 
grow into (and restore) the body's blood cells. 
Pyoderma gangrenosum (PG) 
Disease 
Pyoderma gangrenosum (PG) is a rare noninfectious 
neutrophilic dermatosis first described in 1930. 
Clinically it begins with sterile pustules that rapidly 
progress and turn into painful ulcers of variable depth 
and size with undermined violaceous borders. The legs 
are most commonly affected but other parts of the skin 
and mucous membranes may also be involved. 
Extracutaneous manifestations include involvement of  
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upper airway mucosa, eye, sterile pulmonary 
neutrophilic infiltrates, and neutrophilic myositis. The 
ulcer starts as a follicular pustule with rapid growth, 
tissue necrosis and enlargement of the area. The 
surrounding skin is erythematous with infiltration end 
edema. 
Ulcerative colitis is found in 10-15% of cases. Another 
associated disease is Crohn's regional enteritis with a 
frequency close to that of ulcerative colitis. Hepatitis C, 
seronegative polyarticular arthritis, spondylitis, and a 
broad spectrum of lymphoproliferative disorders  
including monoclonal gammopathies, leukemia, 
lymphoma, and myelodysplastic syndrome have been 
described in association with PG. Two main variants of 
PG exist: classic and atypical.  
Classic PG: characterized by a deep ulceration with a 
violaceous border that overhangs the ulcer bed. May 
occur anywhere on the body; but most commonly 
found on the legs.  
Atypical PG: has a vesciculopustular component only 
at the border, is erosive or superficially ulcerated, and 
most often occurs on the dorsal surface of the hands, 
the extensor parts of the forearms, or the face. 
Prognosis 
Local care: debridement, intralesional injection of 
steroids or cyclosporin, topical agents to alter immune 
response (nitrogen mustard, steroids, acetic acid, 5-
aminosalicylic acid) or inhibit infection. Systemic care: 
glucocorticoids (prednisone). These agents have anti-
inflammatory properties and cause metabolic effects. In 
addition, these agents modify the body's immune 
response to diverse stimuli. Immunosuppressives 
agents (Cyclosporine, Azathioprine, Mycophenolate, 
Cyclophosphamide, Tacrolimus, Chlorambucil) have 
immunomodulatory effects. These agents are used to 
improve the clinical and immunologic aspects of the 
disease. They may decrease autoantibody production 
and increase solubilization and removal of immune 
complexes. Immunomodulators (Thalidomide, 
Clofazimine). 
Sweet's syndrome (SW) 
Disease 
Sweet's syndrome (acute febrile neutrophilic 
dermatosis) is characterized by physical features, and 
pathologic findings which include fever, neutrophilia, 
tender erythematous skin lesions (papules, nodules, and 
plaques), and a diffuse infiltrate consisting 
predominantly of mature neutrophils that are typically 
located in the upper dermis. Sweet's syndrome presents 
in three clinical settings:  
Classical Sweet's syndrome (CSS) usually presents in 
women between the age of 30 to 50 years, it is often 
preceded by an upper respiratory tract infection and 
may be associated with inflammatory bowel disease 
and pregnancy.  
The malignancy-associated Sweet's syndrome (MASS) 
can occur as a paraneoplastic syndrome in patients with  
an established cancer or individuals whose Sweet's 
syndrome-related hematologic dyscrasia or solid tumor 
was previously undiscovered; MASS is most 
commonly related to acute myelogenous leukemia. The 
dermatosis can precede, follow, or appear concurrent 
with the diagnosis of the patient's cancer. 
Drug-induced Sweet's syndrome (DISS) most 
commonly occurs in patients who have been treated 
with granulocyte-colony stimulating factor, however, 
other medications may also be associated with DISS. 
Prognosis 
The pathogenesis of Sweet's syndrome may be 
multifactorial and still remains to be definitively 
established. Systemic corticosteroids are the therapeutic 
gold standard for Sweet's syndrome. Horio et al. 
originally described the dramatic improvement in 
patients with Sweet's syndrome who were treated with 
potassium iodide in 1980. He confirmed his earlier 
observations with a larger study in 1983. Subsequently, 
several other investigators have also observed similar 
improvement when using potassium iodide to treat 
patients with Sweet's syndrome. Vasculitis and 
hypothyroidism are potential drug-induced side effects 
of potassium iodide. Other agents are: colchicine, 
indomethacin, clofazimine, cyclosporin, dapsone. 
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